Transgene Enrolls First Patients in Trial of TG 1042 in CBCL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

Transgene S. A. has announced that the first patients have been enrolled in a two-step phase II trial of its immunotherapy product candidate TG 1042 (Ad-IFNϒ) to treat relapsing cutaneous B-cell lymphoma (CBCL).

STRASBOURG, France—Transgene S. A. has announced that the first patients have been enrolled in a two-step phase II trial of its immunotherapy product candidate TG 1042 (Ad-IFNϒ) to treat relapsing cutaneous B-cell lymphoma (CBCL). TG 1042 is an adenoviral vector containing the human interferon gamma gene. In the first stage, 13 patients will be enrolled at centers in the United States, France, and Switzerland. If results are positive, recruitment will continue with an additional 28 patients in a second confirmatory stage. Patients will receive 4 months of intralesional injections of TG 1042 to induce an anti-tumor immune response. For more information about the trial: go to www.clinicaltrials.gov (search for NCT00394693).

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content